Use of SGLT2 Inhibitors in Patients With Type 2 Diabetes and Chronic Kidney Disease-A Multi-Country Report from the FOUNTAIN Platform

被引：0

作者：

Johannes, Catherine B. ^{[1
]}

Ziemiecki, Ryan ^{[1
]}

Pladevall-Vila, Manel ^{[1
]}

Kosvesdy, Csaba P. ^{[2
]}

Ebert, Natalie ^{[3
]}

Thomsen, Reimar W. W. ^{[4
,5
]}

Christiansen, Christian Fynbo ^{[4
,5
]}

Baak, Brenda ^{[6
]}

Robles Cabaninas, Celia ^{[7
]}

Kashihara, Naoki ^{[8
]}

Yano, Yuichiro ^{[9
]}

Kanegae, Hiroshi ^{[10
]}

Coleman, Craig I. ^{[11
]}

Okami, Suguru ^{[12
]}

Liu, Fangfang ^{[13
]}

Layton, J. Bradley ^{[1
]}

Vizcaya, David ^{[13
]}

Oberprieler, Nikolaus G. ^{[13
]}

机构：

[1] Res Triangle Inst Hlth Solut, Res Triangle Pk, NC USA

[2] Univ Tennessee, Hlth Sci Ctr, Knoxville, TN USA

[3] Charite Univ Med Berlin, Inst Publ Hlth, Berlin, Germany

[4] Aarhus Univ, Dept Clin Epidemiol, Aarhus, Denmark

[5] Aarhus Univ Hosp, Aarhus, Denmark

[6] PHARMO Inst Drug Outcomes Res, Utrecht, Netherlands

[7] FISABIO, Valencia, Spain

[8] Kawasaki Med Sch, Kurashiki, Okayama, Japan

[9] Juntendo Univ, Fac Med, Tokyo, Japan

[10] Genki Plaza Med Ctr Hlth Care, Tokyo, Japan

[11] Univ Connecticut, Storrs, CT USA

[12] Bayer Yakuhin Ltd, Osaka, Japan

[13] Bayer AG, Leverkusen, Germany

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

568

引用

页码：237 / 238

页数：2

共 50 条

[21] Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients
Chen, Xiutian
Wang, Jiali
Lin, Yongda
Yao, Kaijin
Xie, Yina
Zhou, Tianbiao
FRONTIERS IN ENDOCRINOLOGY, 2023, 14
[22] Expanding the Impact of SGLT2 Inhibitors in Chronic Kidney Disease
Makawi, Alaa T.
Tawfik, Yahya M. K.
Dixon, Dave L.
McMahon, Gearoid M.
Buckley, Leo F.
AMERICAN JOURNAL OF NEPHROLOGY, 2024, 55 (04) : 417 - 420
[23] SGLT2 inhibitors should be recommended in patients with one or more of the three diseases: type 2 diabetes, chronic kidney disease, and HFrEF
Zhao, Li-Min
Ding, Liang-Liang
Zhan, Ze-Lin
Qiu, Mei
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2021, 87 : 102 - 103
[24] Another Win for SGLT2 Inhibitors in Chronic Kidney Disease
Leaf, David E.
Bansal, Nisha
NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (08): : 822 - 823
[25] SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
Skrabic, Roko
Kumric, Marko
Vrdoljak, Josip
Rusic, Doris
Skrabic, Ivna
Vilovic, Marino
Martinovic, Dinko
Duplancic, Vid
Kurir, Tina Ticinovic
Bozic, Josko
BIOMEDICINES, 2022, 10 (10)
[26] SGLT2 inhibitors : kidney as a new therapeutic target for type 2 diabetes
Bons, Justine
Prevost, Gaetan
CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2015, 19 (07): : 191 - 195
[27] The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors
Weir, Matthew R.
POSTGRADUATE MEDICINE, 2016, 128 (03) : 290 - 298
[28] SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease
Tuttle, Katherine R.
LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (06): : 414 - 415
[29] CHARACTERISTICS OF MEDICATION-INITIATOR COHORTS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES IN JAPAN: A REPORT FROM FOUNTAIN PLATFORM
Yano, Yuichiro
Kanegae, Hiroshi
Okami, Suguru
Oberprieler, Nikolaus
Pladevall-Vila, Manel
Gay, Alain
Yamashita, Satoshi
Johannes, Catherine
Ebert, Natalie
Kovesdy, Csaba
Vizcaya, David
Kashihara, Naoki
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I558 - I559
[30] SGLT2 INHIBITORS USE IN CHRONIC KIDNEY DISEASE-BETTER CARDIOMETABOLIC PROFILE
Ivandic, Ema
Jelakovic, Ana
Jelakovic, Bojan
Brinar, Ivana Vukovic
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I296 - I296

← 1 2 3 4 5 →